Clinical Trials Logo

Keratosis, Actinic clinical trials

View clinical trials related to Keratosis, Actinic.

Filter by:

NCT ID: NCT01820260 Completed - Actinic Keratosis Clinical Trials

Safety and Efficacy of Ingenol Mebutate Once Daily for 2 or 3 Consecutive Days in Subjects With Actinic Keratosis

Start date: April 2013
Phase: Phase 1/Phase 2
Study type: Interventional

To identify the Maximum Tolerated Dose levels of ingenol mebutate gel after once daily treatment for 2 or 3 consecutive days and to evaluate efficacy of ingenol mebutate gel in different doses after once daily treatment for 2 or 3 consecutive days compared to vehicle gel

NCT ID: NCT01812837 Completed - Actinic Keratosis Clinical Trials

The Use of Microneedles in Photodynamic Therapy

Start date: July 2012
Phase: N/A
Study type: Interventional

The global aim of this study is to investigate how microneedles can facilitate the penetration and efficacy of photodynamic therapy in the treatment of actinic keratoses The specific aims are as follows: 1. Investigate whether pretreatment with microneedles enhances penetration of topical aminolevulinic acid (ALA) that is marketed as Levulan® Kerasticks by DUSA pharmaceuticals Inc. 2. Investigate whether pretreatment with microneedles can decrease the required incubation times of the topical ALA prior to exposure to blue light photodynamic therapy.

NCT ID: NCT01803477 Completed - Actinic Keratosis Clinical Trials

Safety and Dose Finding Study of New Vehicle Formulations Containing Ingenol Mebutate to Treat Actinic Keratosis on the Forearm

Start date: February 2013
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine if the new vehicle formulations containing ingenol mebutate are as safe and effective as Picato® gel 0.05% (it's current vehicle formulation) when applied to AK lesions on the forearm for two consecutive days.

NCT ID: NCT01788007 Completed - Actinic Keratosis Clinical Trials

Clinical Study to Evaluate the Bioequivalence of Two Imiquimod Cream 3.75% Formulations in Patients With Actinic Keratosis.

Start date: January 2013
Phase: Phase 1
Study type: Interventional

The objective of this study is to compare the relative efficacy and safety of the test formulation Imiquimod 3.75% Topical Cream to the marketed formulation Zyclara® (imiquimod) 3.75% Topical Cream in the treatment of actinic keratosis. Both the test and reference formulations will also be compared to a placebo cream to test for superiority.

NCT ID: NCT01787383 Completed - Actinic Keratosis Clinical Trials

A Simultaneous Treatment Regimen Compared to a Sequential Treatment Regimen With Ingenol Mebutate Gel 0.015% and 0.05% of Two Areas With Actinic Keratosis on Face/Scalp and Trunk/Extremities

Start date: February 2013
Phase: Phase 3
Study type: Interventional

The purpose of this trial is to evaluate the safety of a simultaneous treatment regimen compared to a sequential treatment regimen when two separate areas with AKs (one located on face/scalp and the other located on trunk/ extremities) are treated with ingenol mebutate gel

NCT ID: NCT01757613 Completed - Clinical trials for Actinic Keratosis Olsen Grade I/II

Study Whose Purpose is to Find an Optimal Dose for the Treatment With AK 3012 in Patients With Actinic Keratosis

Start date: December 2012
Phase: Phase 2
Study type: Interventional

In this three-armed dose-finding trial 3 AK 3012 topical formulations shall be investigated with respect to safety and efficacy in order to identify the optimal concentration in the topical formulation. The main objective of the trial is to determine the optimal concentration of the active agent in the topical formulation as quantified by the change of the number of skin alterations in pre-defined areas in a time period from inclusion in the trial until the end of treatment (3 months) or prior complete healing.

NCT ID: NCT01742663 Completed - Actinic Keratosis Clinical Trials

A Study Comparing Diclofenac Sodium Gel 3% to Solaraze® Gel 3% in the Treatment of Actinic Keratosis

Start date: October 2012
Phase: Phase 1
Study type: Interventional

The objective of this study is to compare the relative efficacy and safety of the test formulation diclofenac sodium gel 3% (Taro Pharmaceuticals Inc.) to the marketed formulation Solaraze® (diclofenac sodium) Gel 3% (Fougera Pharms) in the treatment of actinic keratosis. Both the test and reference formulations will also be compared to a placebo formulation to test for superiority.

NCT ID: NCT01735097 Completed - Arsenical Keratosis Clinical Trials

Effect of Nigella Sativa in the Treatment of Palmer Arsenical Keratosis

Start date: January 2013
Phase: N/A
Study type: Interventional

Daily intake of Nigella sativa for 12 weeks is effective in the treatment of palmer arsenical keratosis

NCT ID: NCT01731756 Completed - Arsenical Keratosis Clinical Trials

Effects of Leaf Extract of Azadirachta Indica in Palmer Arsenical Keratosis

Start date: January 2013
Phase: N/A
Study type: Interventional

Effects of leaf extract of Azadirachta indica in palmer arsenical keratosis: Randomized, double-blind, placebo-control trial

NCT ID: NCT01703078 Completed - Actinic Keratosis Clinical Trials

Safety and Tolerability of Different Concentrations of an Ingenol Derivative Field Therapy in the Treatment of Actinic Keratosis

Start date: November 2012
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine if the new ingenol derivative gels are as safe as and as well tolerated as ingenol mebutate gel when applied to AK lesions on the forearm for two consecutive days.